問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

List

2449Cases

2018-11-01 - 2021-04-23

Phase III

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

  • Condition/Disease

    Adult Ulcerative Colitis (UC); Adult Crohn′s Disease (CD); acute graft-versus-host disease (aGvHD)

  • Test Drug

    Entyvio (Vedolizumab IV or MLN0002 IV) 300 mg/vial (60 mg/mL)

Participate Sites
7Sites

Terminated7Sites

2019-03-01 - 2023-12-31

Phase III

A Randomized, Controlled Phase 3 Study of Cabozantinib (XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy

  • Condition/Disease

    Advanced Hepatocellular Carcinoma

  • Test Drug

    Cabozantinib (XL184) 20mg and 60mg tablet; Atezolizumab 1200mg/ 20ml solution for IV infusion

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

2019-05-01 - 2023-05-02

Phase II

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

  • Condition/Disease

    Head and Neck Squamous Cell Carcinoma (HNSCC)

  • Test Drug

    Tipifarnib

Participate Sites
8Sites

Recruiting6Sites

Terminated2Sites

2019-11-30 - 2022-05-19

Phase III

A Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy

  • Condition/Disease

    Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis

  • Test Drug

    Momelotinib Tablets；Danazol Capsules

Participate Sites
4Sites

Not yet recruiting3Sites

Recruiting1Sites

2020-02-01 - 2021-01-31

Phase I

A Phase 1a/1b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of EDP 514 in Healthy Subjects (Part 1), and Antiviral Activity in Nucleos(t)Ide Reverse Transcriptase Inhibitor (NUC)-Suppressed Patients With Chronic Hepatitis B Virus Infection (Part 2)

  • Condition/Disease

    Chronic hepatitis B virus (CHB) infection

  • Test Drug

    EDP 514

Participate Sites
10Sites

Recruiting3Sites

Terminated7Sites

2014-07-01 - 2023-10-25

Phase III

Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma

  • Condition/Disease

    Relapsed or Refractory Multiple Myeloma

  • Test Drug

    Daratumumab

Participate Sites
4Sites

Terminated4Sites

葉士芃
China Medical University Hospital

Division of Hematology & Oncology

2014-09-01 - 2019-11-30

Phase II

TIGER-2: A Phase 2, Open-Label, Multicenter, Safety and Efficacy Study of Oral CO 1686 as 2nd Line EGFR-Directed TKI in Patients with Mutant EGFR Non-Small Cell Lung Cancer (NSCLC) with the T790M Resistance Mutation

  • Condition/Disease

    Non-Small Cell Lung Cancer

  • Test Drug

    CO-1686 Hydrobromide Film-Coated Tablets

Participate Sites
5Sites

Terminated5Sites

2015-03-01 - 2019-04-30

Phase III

A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 versus Treatment Choice (TC) in Adults with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy

  • Condition/Disease

    with Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates

  • Test Drug

    SGI-110 for subcutaneous injection

Participate Sites
7Sites

Terminated5Sites

高志平
Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-09-01 - 2018-12-31

Phase II

A Phase 1b/2 Study of MEDI4736 in Combination with Tremelimumab, MEDI4736 Monotherapy, and Tremelimumab Monotherapy in Subjects with Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

  • Condition/Disease

    Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma

  • Test Drug

    Durvalumab (MEDI4736), Tremelimumab

Participate Sites
3Sites

Terminated3Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

趙毅
Taipei Veterans General Hospital

Division of Hematology & Oncology

2015-07-01 - 2018-12-01

Phase II

A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

  • Condition/Disease

    Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    MEDI4736

Participate Sites
5Sites

Terminated5Sites

1 174 175 176 177 178 245
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB